In both cell lines, a KRAS missense mutation is present (H358: KRAS-G12C, A549: KRAS-G12S), as reported in the supplier (ATCC) product sheet, and they are histologically characterized as adenocarcinoma [17]. The gene discussed is KRAS; the disease is adenocarcinoma.